NASDAQ: QTTB · Life Sciences · 6 alerts · CIK 1661998
Share price
$8.29Close, Nov 16
Market cap
$248M
Shares outstanding
29.92MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Q32 Bio Inc. filings on SEC EDGAR ↗
Q32 Bio Inc. reported a net loss of $8.9 million for Q3 2026, with research and development expenses increasing to $5.1 million. The company significantly strengthened its balance sheet during the quarter, ending with $289.6 million in cash and cash equivalents following a $187.5 million follow-on financing and other equity offerings.
Q32 Bio reported third quarter 2026 financial results and provided a corporate update, including clinical data from its SIGNAL-AA trial of bempikibart. The company ended the quarter with $289.6 million in cash, which is expected to fund operations through Phase 3 topline results. Management plans to initiate a registration-directed program for bempikibart in severe alopecia areata in the first half of 2027.
Term
Q3 2026
“The third quarter brought continued momentum for Q32 Bio and our bempikibart program. We shared encouraging SIGNAL-AA Part B results in late-breaking oral and poster presentations at EADV, highlighting bempikibart’s clinically meaningful efficacy data at Week 36 and ability to induce durable responses that were maintained or deepened through the 16-week off-drug period, supporting the potential for less frequent, chronic maintenance dosing”
Jodie Morrison, Chief Executive Officer of Q32 Bio
“We believe our data demonstrates the potential for bempikibart to become a first-line standard of care option for patients with alopecia areata. We are pleased to welcome José and Ellie to lead the advancement of bempikibart into late-stage development and have made key senior appointments spanning clinical operations, clinical strategy and medical affairs, and regulatory affairs.”
Jodie Morrison, Chief Executive Officer of Q32 Bio
Q32 Bio CEO Jodie Pope Morrison Sells $26.8K of Stock
Jodie Pope Morrison, CEO, sold 3,221 shares of Q32 Bio Inc. at $8.32 a share, worth $26.8K in total on Oct 6, 2026. Shares held after the trade: 340,038 (-0.9%).
Q32 Bio CFO and President Lee Kalowski Sells $10.8K of Stock
Lee Kalowski, CFO and President, sold 1,301 shares of Q32 Bio Inc. at $8.32 a share, worth $10.8K in total on Oct 6, 2026. Shares held after the trade: 137,170 (-0.9%).
Q32 Bio presented additional 36-week results and initial 16-week off-drug findings from its SIGNAL-AA Phase 2a trial of bempikibart in patients with severe alopecia areata. The data showed clinically meaningful efficacy, including a 35.3% mean reduction in SALT scores, and supported the drug's advancement into a registration-directed program in the first half of 2027.
“Bempikibart’s robust efficacy data and durability observed across the 36-week treatment period and 16-week off-drug period in both JAK inhibitor-experienced and JAK inhibitor-naïve patients, changes on biomarkers supportive of its bifunctional mechanism, and its favorable safety and tolerability profile support its continued development in a registration-directed program in patients with severe or very severe alopecia areata as well as in expanded alopecia areata populations and other autoimmune and inflammatory indications.”
Jodie Morrison, Chief Executive Officer of Q32 Bio
Q32 Bio appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. Both executives bring extensive experience in late-stage clinical development and regulatory strategy as the company prepares to advance bempikibart into a registration-directed program for alopecia areata in 2027.